USA

‘A little bit of an overreaction’

Abbott Laboratories CEO Robert Ford has opened its company’s packaging every last three months report In a Thursday interview with Jim Cramer from CNBC, he said that Wall Street’s reaction to the results was excessive.

Ford, “I think this is a little too much reaction. Of course, we are all on it.” He said. “We focused on this, but the foundations of the rest of the company is quite robust and this is a point we should really pass.”

Abbott was a top and profitable stroke for the second quarter, while investors were disappointed that the company tightened the full -year gain guidance. Stocks fell more than 8%. Abbott is known for various products and services, including medical devices, diagnosis, nutrition products and generic drugs in the field of health. The company is currently facing a series of cases related to the expert baby formula, but at the end of last year, it has a great win in court.

According to Ford, Abbott’s diagnosis in China was not as strong as expected. However, the company stressed that the company has received recovery in the segment, which pointed to growth in the United States, Europe and Latin America.

Ford said that Abbott wanted to heal the diagnostic business in China as soon as possible, and that it may not happen for several quarters. He said that his company has made management changes and “meets the diagnostic team every week”. However, in the fourth quarter, he said that planning to heal rather than third place was more “cautious”.

Ford said Abbott has seen power in other areas. According to Ford, this job received double -digit growth for several quarters. It connected some of the progress to a “very rich pipeline” of devices, including those who help treat diabetes and heart problems.

He also said Abbott’s general drug business is good in developing markets.

Authorized, “Growing middle class, aging population, higher birth rates, we bring a very large portfolio to these markets,” he said. “And they are looking for companies like Abbott to bring high quality health innovations to the market.”